VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Bordonaro on First-Line Treatment Options for mCRC

Roberto Bordonaro, MD
Published: Friday, Jan 24, 2014

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses first-line treatment options for advanced colorectal cancer (CRC).

Bordonaro says the first-line treatment options for patients with advanced CRC are influenced by RAS mutation status. Physicians have two options for treating patients in this space, Bordonoaro says.

Patients with wild-type RAS are treated with chemotherapy plus anti-EGFR agents, such as panitumumab or cetuximab.

Data from the PRIME trial, which compared FOLFOX plus panitumumab to panitumumab alone, showed that patients treated with panitumumab plus FOLFOX had an improvement in overall survival. The retrospective study of the CRYSTAL study and data from the FIRE study show that cetuximab prolongs overall survival longer than 30 months in patients who have RAS wild-type diease. 
Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses first-line treatment options for advanced colorectal cancer (CRC).

Bordonaro says the first-line treatment options for patients with advanced CRC are influenced by RAS mutation status. Physicians have two options for treating patients in this space, Bordonoaro says.

Patients with wild-type RAS are treated with chemotherapy plus anti-EGFR agents, such as panitumumab or cetuximab.

Data from the PRIME trial, which compared FOLFOX plus panitumumab to panitumumab alone, showed that patients treated with panitumumab plus FOLFOX had an improvement in overall survival. The retrospective study of the CRYSTAL study and data from the FIRE study show that cetuximab prolongs overall survival longer than 30 months in patients who have RAS wild-type diease. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x